# IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer

> **NCT07722494** · PHASE3 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 550 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** IBI363 + bevacizumab
- **DRUG:** Investigator's choice of therapy

## Key facts

- **NCT ID:** NCT07722494
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2028-10-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722494, "IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07722494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*